secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001104659-25-052733
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025
--------------------------------------------------------------------------------

- Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.
- Trial is randomized, double-blind, placebo-controlled; endpoints include safety and lung function (FVC).
- Topline data from the REVERT IPF trial is anticipated in the fourth quarter of 2025.
- TTI-101 targets STAT3, a central mediator of fibrotic signaling pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/0001104659-25-052733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/tm2516173d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer